Jeremy Jones

Assistant Professor

Mayo Clinic

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Jeremy Jones is an Assistant Professor at Mayo Clinic in the United States. His research focuses on gastrointestinal malignancies, particularly advancements in targeted therapies for HER2-overexpressing cancers and KRAS mutations. He has contributed significantly to studies on multigenic cancer testing and the clinical outcomes associated with various treatment modalities in colorectal cancer. His recent publications reflect his commitment to improving patient outcomes through innovative cancer research.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (4)

Andrea Sartore-Bianchi

Associate Professor

Università degli Studi di Torino

ITALY

View details

Richard R. Sharp

UNITED STATES

View details

david tougeron

FRANCE

View details

julien taieb

Professor Head of the department

Université Paris-Saclay

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jeremy Jones

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Tucatinib in the treatment of HER2-overexpressing gastrointestinal cancers: current insights and future prospects

Factors Impacting Intent to Share Multigenic Cancer Testing Results in a Community Hospital Setting

Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting

Advances in Targeting KRAS G12C in Gastrointestinal Malignancies: Focus on KRAS G12C Inhibitors

CLO24-088: Efficacy of Fruquintinib in Less Heavily Pretreated Patients (Pts) With Metastatic Colorectal Cancer (mCRC): Profile-Matched Data From FRESCO and FRESCO-2

Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

A novel anoikis-related gene signature to predict the prognosis, immune infiltration, and therapeutic outcome of lung adenocarcinoma

Association between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated with First-line Pembrolizumab

Proton Therapy With Concurrent Chemotherapy for Thoracic Esophageal Cancer: Toxicity, Disease Control, and Survival Outcomes

Collaborators (4)

Andrea Sartore-Bianchi

Richard R. Sharp

david tougeron

julien taieb

Make your next move.